title: Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.
abstract: The suppression and eradication of primary tumors and distant metastases is a major goal of alternative treatment strategies for cancer, such as inhibition of angiogenesis and targeted immunotherapy. We report here a synergy between two novel monotherapies directed against vascular and tumor compartments, respectively, a tumor vasculature-specific antiangiogenic integrin alphav antagonist and tumor-specific antibody-interleukin 2 (IL-2) fusion proteins. Simultaneous and sequential combination of these monotherapies effectively eradicated spontaneous liver metastases in a poorly immunogenic syngeneic model of neuroblastoma. This was in contrast to controls subjected to monotherapies with either an antiangiogenic integrin alphav antagonist or antibody-IL-2 fusion proteins, which were only partially effective at the dose levels applied. Furthermore, simultaneous treatments with the integrin alphav antagonist and tumor-specific antibody-IL-2 fusion proteins induced dramatic primary tumor regressions in three syngeneic murine tumor models, i.e., melanoma, colon carcinoma, and neuroblastoma. However, each agent used as monotherapy induced only a delay in tumor growth. A mechanism for this synergism was suggested because the antitumor response was accompanied by a simultaneous 50% reduction in tumor vessel density and a 5-fold increase in inflammatory cells in the tumor microenvironment. Subsequently, tumor necrosis was demonstrated only in animals receiving the combination therapy, but not when each agent was applied as monotherapy. The results suggest that these synergistic treatment modalities may provide a novel and effective tool for future therapies of metastatic cancer.
authors.affiliation: The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
authors.forename: H N
authors.initials: HN
authors.lastname: Lode
authors.forename: T
authors.initials: T
authors.lastname: Moehler
authors.forename: R
authors.initials: R
authors.lastname: Xiang
authors.forename: A
authors.initials: A
authors.lastname: Jonczyk
authors.forename: S D
authors.initials: SD
authors.lastname: Gillies
authors.forename: D A
authors.initials: DA
authors.lastname: Cheresh
authors.forename: R A
authors.initials: RA
authors.lastname: Reisfeld
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000502:physiology*; D003110:Colonic Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use*; D039564:Integrin alphaV; D007376:Interleukin-2 / Q000627:therapeutic use*; D008546:Melanoma, Experimental / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D051379:Mice; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D009447:Neuroblastoma / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012910:Snake Venoms; D014407:Tumor Cells, Cultured